JP2021525278A5 - - Google Patents
Info
- Publication number
- JP2021525278A5 JP2021525278A5 JP2021515306A JP2021515306A JP2021525278A5 JP 2021525278 A5 JP2021525278 A5 JP 2021525278A5 JP 2021515306 A JP2021515306 A JP 2021515306A JP 2021515306 A JP2021515306 A JP 2021515306A JP 2021525278 A5 JP2021525278 A5 JP 2021525278A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- group
- optionally substituted
- aryl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023191446A JP7653092B2 (ja) | 2018-05-24 | 2023-11-09 | フルベストラントのプロドラッグ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201821019542 | 2018-05-24 | ||
| IN201821019542 | 2018-05-24 | ||
| IN201821047939 | 2018-12-18 | ||
| IN201821047939 | 2018-12-18 | ||
| PCT/IB2019/054315 WO2019224790A2 (en) | 2018-05-24 | 2019-05-24 | Prodrugs of fulvestrant |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023191446A Division JP7653092B2 (ja) | 2018-05-24 | 2023-11-09 | フルベストラントのプロドラッグ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525278A JP2021525278A (ja) | 2021-09-24 |
| JP2021525278A5 true JP2021525278A5 (enExample) | 2022-06-13 |
| JP7384903B2 JP7384903B2 (ja) | 2023-11-21 |
Family
ID=68615936
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021515306A Active JP7384903B2 (ja) | 2018-05-24 | 2019-05-24 | フルベストラントのプロドラッグ |
| JP2023191446A Active JP7653092B2 (ja) | 2018-05-24 | 2023-11-09 | フルベストラントのプロドラッグ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023191446A Active JP7653092B2 (ja) | 2018-05-24 | 2023-11-09 | フルベストラントのプロドラッグ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210253626A1 (enExample) |
| EP (1) | EP3801553B1 (enExample) |
| JP (2) | JP7384903B2 (enExample) |
| AU (1) | AU2019274815B2 (enExample) |
| CA (1) | CA3101421C (enExample) |
| WO (1) | WO2019224790A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7384903B2 (ja) * | 2018-05-24 | 2023-11-21 | ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | フルベストラントのプロドラッグ |
| EP4061376A4 (en) * | 2019-11-24 | 2024-03-13 | Kashiv Biosciences, LLC | Prodrugs of fulvestrant |
| WO2021172359A1 (ja) * | 2020-02-25 | 2021-09-02 | 大日本住友製薬株式会社 | Ｃｄｋ９阻害剤プロドラッグ及びそれを内封するリポソーム |
| WO2022034587A1 (en) * | 2020-08-10 | 2022-02-17 | Tnik Therapeutics Ltd | Traf2- AND Nck-INTERACTING KINASE (TNIK) INHIBITORS AND USES THEREOF |
| CA3230353A1 (en) * | 2021-08-23 | 2023-03-02 | Sumitomo Pharma Co., Ltd. | Self degradation-type cdk9 inhibitor prodrug and liposome encapsulating same |
| EP4422636A4 (en) * | 2021-10-29 | 2025-09-03 | Kashiv Biosciences Llc | INECTABLE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF BREAST CANCER |
| WO2023103929A1 (zh) * | 2021-12-06 | 2023-06-15 | 江苏亚虹医药科技股份有限公司 | 氟维司群衍生物及其制备方法和医药用途 |
| EP4444318A4 (en) * | 2021-12-06 | 2026-01-28 | Amneal Pharmaceuticals Llc | COMPOUNDS FOR CANCER TREATMENT |
| CN119751533B (zh) * | 2025-03-10 | 2026-01-13 | 山东大学 | 一种基于雌甾三烯结构的雌激素受体蛋白靶向降解嵌合体衍生物及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| GB0008172D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Therapy |
| CN102600073B (zh) * | 2012-03-31 | 2014-01-01 | 莱普德制药有限公司 | 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法 |
| US20160060288A1 (en) * | 2013-04-18 | 2016-03-03 | Xi'anlibang Pharmaceutical Technology Co., Ltd. | Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof |
| CN103421069A (zh) | 2013-05-23 | 2013-12-04 | 中国海洋大学 | 氟维司群磷酸酯衍生物及其制备方法和应用 |
| US10112962B2 (en) | 2014-07-02 | 2018-10-30 | Xavier University | Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group |
| WO2019050850A1 (en) * | 2017-09-05 | 2019-03-14 | Primetime Life Sciences, Llc | BIGUANIDINE DERIVATIVES OF THERAPEUTIC AGENTS, AND PREPARATION METHODS AND METHODS OF USING SAME |
| CN108159055A (zh) * | 2018-01-04 | 2018-06-15 | 西安力邦医药科技有限责任公司 | 治疗乳腺癌的长效递药系统、其制备方法及应用 |
| JP7384903B2 (ja) * | 2018-05-24 | 2023-11-21 | ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | フルベストラントのプロドラッグ |
-
2019
- 2019-05-24 JP JP2021515306A patent/JP7384903B2/ja active Active
- 2019-05-24 CA CA3101421A patent/CA3101421C/en active Active
- 2019-05-24 EP EP19808360.2A patent/EP3801553B1/en active Active
- 2019-05-24 US US17/058,390 patent/US20210253626A1/en active Pending
- 2019-05-24 WO PCT/IB2019/054315 patent/WO2019224790A2/en not_active Ceased
- 2019-05-24 AU AU2019274815A patent/AU2019274815B2/en active Active
-
2023
- 2023-11-09 JP JP2023191446A patent/JP7653092B2/ja active Active